Aripiprazole is an antipsychotic drug, which works on receptors and transporters. This drug performs its action by binding and by blocking the receptors. This was allowed to use by United States Food and Drug Administration in 2002 to deal the cases ofschizophrenia. ...
P.3.c.003 A real picture on treatment with aripiprazole to long-time on metabolic syndromearterial hypertensiondiabetesLatin American consensusmetabolic syndromeThe present document has been prepared by a group of experts, members of cardiology, endocrinology and diabetes societies of Latin American ...
Olanzapine (10 mg/die) was discontinued, and a low dose of clozapine (12,5 mg/die) was introduced, without any exacerbation of the psychiatric disorder, and without modification of chorea. After a few days, tetrabenazine was introduced and gradually titrated up to 75 mg/die in two weeks. ...
Systemic Perturbation of the ERK Signaling Pathway by the Proteasome Inhibitor, MG132. PLoS ONE 2012, 7, e50975. [Google Scholar] [CrossRef] Sandstrom, A.; Mitchell, P.S.; Goers, L.; Mu, E.W.; Lesser, C.F.; Vance, R.E. Functional degradation: A mechanism of NLRP1 inflammasome...